Genentech, Inc
Article Abstract:
A comparative analysis of the company sales and financial details of Genetech, Inc. from 1994 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Genentech Inc
Article Abstract:
Genentech Inc. achieved a 25% average in annal profit growth, expected to continue to 2005. Equity is timely and offers decent capital appreciation potential to 2006-2008.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Genentech, Inc
Article Abstract:
The price appreciation potential of Genentech, Inc. for the years 2010-2012 is discussed. The San Francisco, California-based company produces drugs for cancer and asthma.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
User Contributions:
Comment about this article or add new information about this topic: